Press releases

Release issued 25th July 2007

York, UK, 25 July 2006 - Last year the pharmaceutical and biotech industry generated over $16 billion through deals and alliances, illustrating big pharma’s desperation to secure potential products for incomplete pipelines. In-licensed products now generate over 30% of the revenues of the major pharmaceutical companies and many ‘blockbusters’ of recent years have a history of cross-company licensing.
Today Pharmalicensing launches the 3^rd edition of its top selling report ‘The Licensing Agreement in Pharmaceutical Business Development’. The revised report is a complete guide to the licensing agreement, covering key terms, IP rights, patents, regulations and contract law.

Ideal for lawyers and dealmakers negotiating a potential deal, the report provides readers with a deeper understanding of the legalities involved. Experienced Lawyer and author Paul Ranson covers all the hurdles associated with a typical licensing agreement including negotiation statements, confidentiality agreements, due diligence and manufacturing and supply.

The report is multi-dimensional, not only does it consider licensing from both a European and US perspective, it also covers the complex subject of contract termination.

Licensing is not always straight forward and can often be a tricky subject to grasp hold of. However sufficient knowledge is required to conduct high level discussions with senior experienced professionals. This report examines the key factors that must be considered when drawing up a suitable contract and acts a reference source for anyone entering into a deal. It also brings those already familiar with licensing up to date with the current regulations and trends operating today.

The first version of the report was originally published in 2003 and this was followed by the second edition in April 2005. Today in 2007 we have the third improved edition of the report covering new items to consider in today’s lucrative licensing environment.  

For more information about this report or to order your copy, contact our team on tel: +44 1904 520460 or email: sales@pharmalicensing.com

Pharmalicensing Ltd (pharmalicensing.com), based in York, UK, is the leading online global resource for partnering, licensing and business development within the life science and biopharmaceutical industry.

Contact: Johan Ohlsson, Strategic Analyst, Business Development (johan.ohlsson@pharmalicensing.com; Tel +44 1904 520491)

(20th May 2013) Pharmalicensing and Bionow sign strategic marketing and member benefit agreement

(5th January 2012) Innovaro Announces Successful Sale of the Waycool Portfolio of Patents by CUI Global, Inc.

(28th January 2010) New collaboration presents big opportunities for UK SMEs

(14th January 2010) UTEK Pharmalicensing.com Announces New Pricing Model: Pay-per-Click to Expand Listed Opportunities, Extend Reach and Remove Market Barriers

(4th January 2008) UTEK Corporation Acquires Pharmalicensing, Ltd.